For research use only. Not for therapeutic Use.
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget agent candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD agent development[1].
PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) [1].
| Catalog Number | I018666 |
| CAS Number | 2089415-51-8 |
| Synonyms | (1-benzylpiperidin-4-yl)methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate |
| Molecular Formula | C23H27NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H27NO4/c1-27-22-15-18(7-9-21(22)25)8-10-23(26)28-17-20-11-13-24(14-12-20)16-19-5-3-2-4-6-19/h2-10,15,20,25H,11-14,16-17H2,1H3/b10-8+ |
| InChIKey | QJDRBHVMOOPIGE-CSKARUKUSA-N |
| SMILES | COC1=C(C=CC(=C1)C=CC(=O)OCC2CCN(CC2)CC3=CC=CC=C3)O |
| Reference | [1]. Morroni F, et al. PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer’s Disease. Front Pharmacol. 2019 Jun 12;10:658. |
